Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-04-12
2005-04-12
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S023000, C514S057000
Reexamination Certificate
active
06878749
ABSTRACT:
The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises nateglinide (1) stetor repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases and conditions associated with diabetes; to a composition, respectively, which comprises nateglinide and a pharmaceutically acceptable carrier and to a process of making such composition; the use of such combination or composition for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders; a method of prevention, delay of progression or treatment of diseases in warm-blooded animals; the use of such combination or composition for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight; and to a method of improving the bodily appearance of a warm-blooded animal.
REFERENCES:
patent: 3174901 (1965-03-01), Sterne
patent: 3536809 (1970-10-01), Applezweig
patent: 3561444 (1971-02-01), Boucher
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3630200 (1971-12-01), Higuchi
patent: 3703173 (1972-11-01), Dixon
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4287200 (1981-09-01), Kawamatsu et al.
patent: 4309404 (1982-01-01), Guley et al.
patent: 4309406 (1982-01-01), Guley et al.
patent: 4556552 (1985-12-01), Porter et al.
patent: 4624251 (1986-11-01), Miller
patent: 4635627 (1987-01-01), Gam
patent: 4704295 (1987-11-01), Porter et al.
patent: 4816484 (1989-03-01), Toyoshima et al.
patent: 4997948 (1991-03-01), Zask et al.
patent: 5216167 (1993-06-01), Grell et al.
patent: RE34878 (1995-03-01), Toyoshima et al.
patent: 5463116 (1995-10-01), Sumikawa et al.
patent: 5488150 (1996-01-01), Sumikawa et al.
patent: 5952356 (1999-09-01), Ikeda et al.
patent: 5955106 (1999-09-01), Moeckel et al.
patent: 6020382 (2000-02-01), Doebber et al.
patent: 6153632 (2000-11-01), Rieveley
patent: 6559188 (2003-05-01), Gatlin et al.
patent: 19860699 (2000-07-01), None
patent: 139 421 (1985-05-01), None
patent: 193 256 (1986-09-01), None
patent: 196 222 (1986-10-01), None
patent: 207 605 (1989-01-01), None
patent: 306 228 (1989-03-01), None
patent: 332 332 (1989-09-01), None
patent: 526 171 (1993-02-01), None
patent: 604 983 (1994-07-01), None
patent: 749 751 (1996-12-01), None
patent: 0 965 339 (1999-12-01), None
patent: 10087641 (1998-04-01), None
patent: WO 9822105 (1998-05-01), None
patent: WO 9856378 (1998-12-01), None
patent: WO 0027401 (2000-05-01), None
Arakawa et al., “Actions of Novel Antidiabetic Thiazolidinedione, T-174, in Animal Models of Non-Insulin-Dependent Diabetes Mellitus (NIDDM) and In Cultured Muscle Cells”, British J. of Pharma., vol. 125, pp. 429-436 (1998).
Diabetes Control and Complications Trial Research Group, “The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-term Complications in Insulin-Dependent Diabetes Mellitus”, New England J. of Med., vol. 329, No. 14, pp. 977-986 (1993).
Goldstein et al., “Tests of Glycemia in Diabetes”, Diabetes Care, vol. 18, No. 6, pp. 896-909 (1995).
Lohray et al., “Novel Euglycemic and Hypolipidemic Agents. 1”, J. Med. Chem., pp. 1619-1930 (1998).
Mendes et al., “Tableting Excipients”, Pharmaceutical Technology, pp. 61-66, 109 (1978).
Mendes et al.“Tableting Excipients”, Pharmaceutical Technology, pp. 69-75, 100 (1979).
Noshiro et al., “Role of Plasma Insulin Concentration in Regulating Glucose and Lipid Metabolism in Lean and Obese Zucker Rats”, Int'l J. Obesity, pp. 115-121 (1997).
Ueda et al., “Pharmacological and Pharmacokinetic Studies of the Newly Synthesized Thiazolidinedione Derivative 5-(4-(1-Phenyl-1-cyclopropanecarbonylamino)benzyl)-thiazoline-2,4-dione”, Arzneim.-Forsch./Drug Research, vol. 48, No. 6, pp. 651-657 (1998).
Wrobel et al., “Novel 5-(3-Aryl-2-propynyl)-5-(arylsulfonyl)thiazolidine-2,4-diones as Antihyperglycemic Agents”, J. Med. Chem., vol. 41, pp. 1084-1091 (1998).
Zhang et al., “Potentiation of Insulin Stimulation of Phosphatidylinositol 3-Kinase by Thiazolidinedione-derived Antidiabetic Agents in Chinese Hamster Ovary Cells Expressing Human Insulin Receptors and L6 Myotubes”, J. Bio. Chem., vol. 269, No. 41, pp. 25735-25741 (1994).
Dunning, “Nateglinide: A Glucose-Sensitive Insulinotropic Agent That is Chemically and Pharmacologically Distinct From the Sulfonylureas”, Curr. Opin. Endocrinol. Diabetes, No. 6 (Suppl. 1), pp. S29-S31 (1999).
“Huge Interest in Rosiglitazone and Pioglitazone”, SCRIP, No. 2451, pp. 28-30 (1999).
Newman, “Aerosols and the Lung: Clinical and Experimental Aspects”, (S.W. Clarke and D. Pavia, Eds.), Butterworths, Longon, England, pp. 197-224 (1984).
United States Pharmacopoeia, 23rd Edition, pp. 2253-2254.
Moses et al., “Flexible Meal-Related Dosing With Repaglinide Facilitates Glycemic Control in Therapy-Naive Type 2 Diabetes”, Diabetes Care, vol. 24, No. 1, pp. 11-15 (2001).
Fessler, “Nateglinide Regulates Blood Glucose After Meals”, Deutsche Apotheker Zeitung, vol. 140, No. 30, pp. 30-31 (2000)—[2000292172 EMBASE].
“Oral Therapy of Type 2 Diabetes: Nateglinide Intake is Effective During the Meal”, Deutsche Apotheker Zeitung, vol. 139, No. 46, pp. 32-33 (1999)—[1999419885 EMBASE].
Megumi et al., “Hypoglycemic Effect of a Novel Antidiabetic Agent, AY4166, in Normal and Diabetic Rats”, Kiso to Rinsho (Clinical Report), vol. 31, No. 5, pp. 1725-1735 (1997)—[970516374 (JICST-Eplus].
Hiroshi et al., “Treatment of Diabetes Mellitus. How is the New Drug Positioned? Positioning of the Therapeutic Drug and Pitfall in the Application. Rapid Action Insulin Secretagogue.”, Clinics & Drug Therapy, vol. 19, No. 8, pp. 778-783 (2000)—Abstract No. 1000743920 JICST-EPlus.
Hiroshi et al., “Treatment of Diabetes Mellitus. How is the New Drug Positioned? Positioning of the Therapeutic Drug and Pitfall in the Application. .ALPHA.-Glucosidase Inhibitor.”, Clinics & Drug Therapy, vol. 19, No. 8, pp. 785-789 (2000)—Abstract No. 1000743921 JICST-EPlus.
Kazunori et al., “Usage Experience of Nateglinide for Diabetes Mellitus Type 2”, Japanese Journal of Clinical and Experimental Medicine, vol. 77, No. 4, pp. 866-869 (2000)—Abstract No. 1000504530 JICST-Eplus.
Masatoshi et al., “The Safety and Efficacy of Combination Therapy of AY4166 and Sulfonylurea in Patients with NIDDM”, Clinical Pharmacology and Therapy, vol. 7, No. 5, pp. 755-766 (1997)—Abstract No. 970577231 JICST-EPlus.
Marre et al., “Nateglinide Added to Metformin Offers Safe and Effective Treatment for Type 2 Diabetes”, Diabetes, vol. 49, Supp. 1, p. 1517 (2000)—Abstract No. 2000:576788 SCISEARCH.
Gatlin et al., “Nateglinide Improves Glycernic Control Alone and in Combination with Troglitazone in Type 2 Diabetes”, Diabetologia, vol. 43, Suppl. 1, p. 722 (2000)—Abstract No. 2000:814174 SCISEARCH.
Dunn et al., “Nateglinide”, Drugs, vol. 60, No. 3, pp. 607-615 (2000)—Abstract No. 2000:738604 HCAPLUS.
Dunning, “New Non-Sulfonylurea Insulin Secretagogues”, Expert Opin. Invest. Drugs, vol. 6, No. 8, pp. 1041-1048 (1997)—Abstract No. 1997:551526 HCAPLUS.
Hirschberg, “Improved Control of Mealtime Glucose Excursions With Coadministration of Nateglinide and Metformin”, Diabetes Care, vol. 23, No. 3, pp. 349-353 (2000)—Abstract No. 132:329758p Chemical Abstracts.
Horton, “Nateg
Allison Malcolm
Ball Michele Ann
Gatlin Marjorie Regan
Guitard Christiane
Karnachi Anees Abdulquadar
Ferraro Gregory D.
Novartis AG
Thallemer John D.
Weddington Kevin E.
Wilusz Edward J.
LandOfFree
Method of treating metabolic disorders, especially diabetes,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating metabolic disorders, especially diabetes,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating metabolic disorders, especially diabetes,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3428550